Ethanol Inhibits Fibroblast Growth Factor–Induced Proliferation of Aortic Smooth Muscle Cells

Giancarlo Ghiselli, Jia Chen, Mohamad Kaou, Hazam Hallak, Raphael Rubin

Objective—Epidemiological studies have demonstrated that moderate alcohol consumption reduces mortality associated with coronary artery disease. The protective effect is correlated with the amount of ethanol consumed but is unrelated to the form of alcoholic beverage. Adoption of a favorable lipoprotein profile accounts for about half of the protective action of alcohol, but the remaining causative factors remain conjectural. Fibroblast growth factors (FGFs) play important roles in mediating smooth muscle cell (SMC) proliferation and migration, which are key factors in the atherosclerotic process. In the present study, we examined the effect of ethanol on FGF-mediated SMC growth and signaling.

Methods and Results—Pharmacologically relevant concentrations of ethanol inhibited the proliferation of a rat aortic SMC line (SV40LT-SMCs) in response to FGF1 and FGF2. Human aortic SMC growth was similarly inhibited by ethanol. Transition into the G2/M phase was specifically affected. FGF-mediated phosphorylation of p42/p44 mitogen-activated protein kinase (MAPK) c-Raf, MAP kinase kinase kinase, MEK1/2 MAP kinase, kinase, stress-activated protein kinase/c-Jun–NH2-terminal kinase, and p38 MAPK were variably reduced by ethanol. The inhibition of intracellular signaling by ethanol was correlated with inhibition of FGF receptor autophosphorylation. By contrast, neither epidermal growth factor receptor autophosphorylation nor epidermal growth factor–mediated p42/p44 MAPK activation was affected by ethanol.

Conclusions—The findings identify the FGF receptor as an inhibitory target for ethanol, which could account in part for the inhibitory actions of ethanol on SMC proliferation observed in vivo. (Arterioscler Thromb Vasc Biol. 2003;23:1808-1813.)

Key Words: atherosclerosis ■ ethanol ■ fibroblast growth factor ■ cell cycle ■ aortic smooth muscle cells
stream of the FGFR and inhibition of FGFR-2 tyrosine autophosphorylation. The findings identify FGFR-2 as an inhibitory target of ethanol action.

**Methods**

**Cell Cultures**

SV40-immortalized rat aortic SMCs (SV40LT-SMCs) and human aortic SMCs (T/G HA-VSMCs) were obtained from American Type Culture Collection. Human cells were grown in dishes coated with rat tail type I collagen (BD-Biotech). SV40LT-SMCs were maintained in Dulbecco’s minimal essential medium supplemented with 10% fetal calf serum, penicillin (100 IU/mL), streptomycin (100 μg/mL), and G418 (100 μg/mL, Mediatech). T/G HA-VSMCs were maintained in MDCB-131 SMC proliferation medium (BD-Biotech) supplemented with 5% fetal calf serum and human recombinant FGF2 (2 ng/mL), epidermal growth factor EGF (0.5 ng/mL), and insulin (5 μg/mL, Sigma).

**Cell Growth Assays**

Cells were seeded at a density of 10 000 cells/cm² in 12-well plates and cultured overnight. The cells were incubated for 24 hours in serum-free medium 199 (BD-Biotech) supplemented with 0.2% bovine serum albumin and human recombinant FGF2 (2 ng/mL), epidermal growth factor EGF (0.5 ng/mL), and insulin (5 μg/mL, Sigma). Growth factors were then added with or without ethanol. To compensate for the evaporation of ethanol, the medium was replaced daily. At selected times, cells were harvested by trypsinization and counted as described earlier. Assays were performed by adding MTS directly to the culture wells, incubating them for 30 minutes, and then recording the absorbance at 490 nm with a 96-well plate spectrophotometric reader (Dynatech MR600).

**Cell Cycle Analysis**

Subconfluent cells were incubated for 24 hours with 50 ng/mL FGF2 in the presence or absence of 85 mmol/L ethanol. After trypsinization, cells were fixed in 70% ethanol and incubated in 200 μg/mL RNase A and 10 μg/mL propidium iodine for 30 minutes. Flow cytometry was performed with a commercially available instrument (Coulter Epics).

**Western Immunoblotting**

Cells were lysed in 50 mmol/L Tris-HCl–150 mmol/L NaCl, pH 7.5, buffer containing 1% Nonidet P40, 0.5% sodium deoxycholate, 100 mmol/L NaF, 2 mmol/L NaVO₃, 10 mmol/L phenylmethylsulfonylfluoride, 500 μmol/L 4-(2-aminoethyl)-benzenesulfonylfluoride, 150 mmol/L aprotinin, and 1 μmol/L leupeptin. Five micrograms of protein was electrophoresed in 12% sodium dodecyl sulfate denaturing polyacrylamide slab gels. After transfer to nitrocellulose membranes, bands were visualized by reaction with specific anti-phosphoprotein antibodies directed against phospho–c-Raf, phospho–mitogen-activated protein kinase kinase/extracellular signal–regulated kinase 1/2 (MEK1/2), phospho–p42/p44 mitogen-activated protein kinase/Erk1/2 (MAPK), phospho–stress-activated protein kinase/c-Jun–NH₂-terminal kinase (SAPK/JNK), and phospho–p38 MAPK (Cell Signaling). In brief, membranes were blocked in 5% bovine serum albumin and probed with antibody to phospho–c-Raf, phospho–MAPK, phospho–SAPK/JNK, and phospho–p38 MAPK proteins. Blots were visualized by reaction and exposed for autoradiography.

**Statistics**

Groups of data were analyzed by a 2-tailed Student’s t test.

**Results**

**FGFR Expression in Rat SV40LT-SMCs**

The rat aortic SMC (SV40LT-SMC) cell line maintains defined SMC characteristics for >200 population doublings, including muscle-specific actin expression and growth inhibition by heparin.²⁻⁴ It displays a low proliferative rate in serum-free medium while maintaining its phenotype. By contrast, cultures of SMCs from rat and human aortic explants can be maintained in culture for only a few passages and do not survive serum-free conditions for more than 24 to 48 hours. Thus, SV40-LT SMCs were used for studies of ethanol effects on SMC proliferation.

The FGFR expression pattern of SV40LT-SMCs is shown Figure 1. Blotting for FGFR-2 revealed 2 major bands at ~115 and 100 kDa and another of lower intensity at 65 kDa. The 115-kDa band has the same size as the phospho–c-Raf receptor and likely corresponds to the intact receptor or to the largest of the splicing variants expressed by this cell line.²⁴
The 100- and 65-kDa bands might represent proteolytic products of FGFR-2. Their intensities were not affected by ethanol, nor were they phosphorylated. FGFR-1 was undetectable in SV40LT-SMCs (not shown). Positive controls for the anti–FGFR-1 antibody were demonstrated in colon carcinoma cell lines HCT116 and WiDr (not shown).

Ethanol Inhibits FGF-Dependent SMC Proliferation

FGF1 and FGF2 are both ligands for FGFR-2,24 and an autocrine loop of FGF has been identified in SMCs, which is necessary for the survival of these cells in culture.25 SV40LT-SMCs proliferated minimally in serum-free medium. Both FGF1 and FGF2 at 50 ng/mL induced SMC proliferation at a rate equivalent to that observed in the presence of 10% fetal calf serum (not shown). Ethanol (85 mmol/L) had minimal effect on the basal proliferative rate in serum-free medium alone but significantly decreased FGF1- and FGF2-induced proliferation (Figure 2) without causing cell detachment or death. The effect of ethanol on the FGF1- and FGF2-mediated proliferation was, however, different. Whereas 20 mmol/L ethanol was sufficient to maximally affect cell growth in response to FGF2 (77% inhibition), FGF1-induced proliferation required much higher ethanol concentrations (45% inhibition with 85 mmol/L ethanol; online Figure I at http://atvb.ahajournals.org). Maximal cell growth was observed at 50 ng/mL FGF1 and FGF2. Higher concentrations of FGF1 partially overcame the effect of ethanol (57% inhibition at 150 ng/mL FGF1), whereas inhibition by ethanol was not counteracted by even 150 ng/mL FGF2 (online Figure II). Ethanol had a similar effect on the FGF-mediated proliferation of human aortic SMCs (T/G HA-V SMCs). At 85 mmol/L, ethanol completely inhibited FGF1- and FGF2-dependent growth stimulation and reduced basal cell growth in the absence of FGF by ≈20% (online Figure III).

Accelerated G1 arrest and a prolonged S-phase transition have been reported in cells after exposure to ethanol.26,27 Cell cycle parameters for SV40LT-SMC growth were determined by flow cytometry (the Table). Cells were treated with FGF2 (50 ng/mL) for 24 hours. Ethanol by itself (85 mmol/L) decreased the number of mitotic cells (in the G2/M phase) by 23% (P<0.05). FGF-dependent acceleration of cell entry into the S and G2/M phases and the concomitant reduction in G1 phase cells were completely inhibited by ethanol.

Ethanol Inhibits FGF-Mediated MAPK Activation

FGF2 induced the tyrosine phosphorylation of c-Raf, MEK1/2, SAPK/JNK, and p42/p44 and p38 MAPKs (Figure 3). Reductions in the phosphorylation of MEK1/2 and of p42/p44 and p38 MAPKs were observed at 85 mmol/L ethanol, and there was complete inhibition at 170 mmol/L ethanol. The phosphorylation of SAPK/JNK and c-Raf was also affected by ethanol but only at the higher ethanol concentration. The low basal levels of p42/p44 MAPK and SAPK/JNK phosphorylation were reduced by 85 mmol/L ethanol. In contrast with the inhibition of p42/p44 MAPK phosphorylation by FGF, ethanol had no effect on EGF-induced p42/p44 MAPK phosphorylation (Figure 4). The phosphorylation of MAPK in response to EGF was maintained even after 24 hours of incubation with ethanol.

Ethanol Inhibits FGFR-2 Phosphorylation

Given the multiple sites of ethanol inhibition in FGF signaling, we next considered whether ethanol inhibits the tyrosine autophosphorylation of FGFR-2 (Figure 5). Ethanol had little or no effect on the constitutive level of FGFR-2 tyrosine autophosphorylation but strongly inhibited its phosphorylation.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>G1</th>
<th>S</th>
<th>G2/M</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>69.4±1.5</td>
<td>18.1±1.7</td>
<td>12.4±1.5</td>
</tr>
<tr>
<td>Ethanol (85 mmol/L)</td>
<td>75.7±2.3*</td>
<td>14.9±2.4*</td>
<td>9.5±1.2*</td>
</tr>
<tr>
<td>FGF2 (50 ng/mL)</td>
<td>64.2±1.0*</td>
<td>22.1±0.5*</td>
<td>13.6±0.8</td>
</tr>
<tr>
<td>FGF2 (50 ng/mL)/Ethanol (85 mmol/L)</td>
<td>69.3±1.4†</td>
<td>19.6±1.3†</td>
<td>11.1±0.8†</td>
</tr>
</tbody>
</table>

Values are mean±SD; n=5. *P<0.05 vs untreated group; †P<0.05 vs FGF2 alone group
tion by FGF2. By contrast, ethanol had no effect on EGF-induced EGFR autophosphorylation.

Discussion
Recent animal studies have demonstrated that ethanol inhibits arterial intimal hyperplasia. Long-term alcohol feeding inhibits the progression of atherosclerosis in C57BL/6 hyperlipidemic mice and reduces vascular cell proliferation in hypercholesterolemic rabbits after balloon angioplasty. Considerable reductions in neointimal hyperplasia, including SMC proliferation, were also observed in pigs after angioplasty. Interestingly, in the last model, local delivery of 15% ethanol in the immediate postinjury phase was effective in reducing the size of neointimal lesions, which suggests that early signaling events might be specifically targeted by ethanol. Ethanol-induced inhibition of rat vascular SMC proliferation and activation of p42/p44 MAPK in vitro was subsequently demonstrated. Taken together, ethanol appears to reduce SMC growth, an effect that has been invoked to participate in the protective action of moderate alcohol consumption on the complications of coronary heart disease and ischemic stroke.

In the current study, we have identified the FGF signaling pathway in SMCs as an inhibitory target for ethanol. Pharmacologically relevant concentrations of ethanol potently inhibited FGF-induced SMC proliferation. FGF1 and FGF2 mitogenic activities were differently affected by ethanol. Interestingly, whereas FGF2 stimulates its own biosynthesis through an autocrine loop, FGF1 is unable to do so. Conceivably, ethanol inhibition of the FGF2 effect is amplified through a blockade of the autocrine loop. Because of the higher mitogenic potency and susceptibility to ethanol dis-
played by FGF2, signaling studies were carried out with this growth factor.

Ethanol inhibited the proximal step in FGF-mediated signaling, FGF-2 tyrosine autophosphorylation, and variably inhibited the phosphorylation of several intracellular signaling molecules downstream of FGF-2, including c-Raf, MEK 1/2, SAPK/JNK, and p38 and p42/p44 MAPKs. By contrast, EGF signaling was unaffected by ethanol in SMCs, in terms of both EGFR autophosphorylation and activation of p42/p44 MAPK. EGF has been reported to be a mitogen for SMCs in culture. However, to date, no role for EGF as an autocrine stimulus in these cells has been identified. Pastore et al. reported that an EGFR-targeted cytotoxin inhibits neointimal neoplasia in vivo. In another study, Trieu et al. found that selective inhibition of the EGFR decreased neointimal hyperplasia after vascular injury. In several cell types (eg, glia, neuronal cells), ethanol inhibits growth stimulation in response to other growth factors, including IGF-1, IRS-2, and Shc to ethanol. Notably, the EGFR is not directly inhibited by ethanol in neuronal cells and hepatocytes (R. Rubin, unpublished data), as well as SMCs in the current study. Given the structural similarities among the ethanol-sensitive RTKs, it is possible that ethanol interferes with the basic mechanism of kinase activation, perhaps at the level of activation-loop engagement.

As for receptor tyrosine kinases (RTKs) in general, signaling downstream of the FGFR is complex. However, p42/p44 MAPK has been invoked as a gatekeeper for SMC proliferation. Moreover, specific inhibitors of MAPK phosphorylation markedly inhibit SMC growth. This dependence of SMC growth on MAPK activation has been documented in vivo, in which the marked increase in p42/p44 MAPK phosphorylation after balloon catheter injury of the rat carotid artery can be effectively prevented by administering specific MEK inhibitors. In the current study, the inhibition of SMC growth was correlated with a reduction in FGF-dependent MAPK activation. Ethanol also reduced the basal level of MAPK phosphorylation. For several reasons, however, it is unlikely that MAPK is directly targeted by ethanol. Importantly, in the current study, ethanol had no effect on EGF-induced MAPK activation. Ethanol also did not inhibit MAPK activation in response to phorbol ester, which bypasses receptor activation (data not shown). Given the basal phosphorylation of MAPK, even after serum starvation, it is likely that ethanol impairs the autocrine stimulation of MAPK, perhaps via inhibition of autocrine FGF-dependent stimulation. By extension, we suggest that ethanol-induced inhibition of the FGF signaling axis could account for the impairment of SMC growth in the presence of serum.

In several cell types (eg, glia, neuronal cells), ethanol inhibits growth stimulation in response to other growth factors that signal via RTKs, including insulin, insulin growth factor (IGF)-I, and platelet-derived growth factor. Given the multiplicity of growth factors contained within serum, in conjunction with regulation of growth by autocrine and paracrine stimulation by growth factors, it is possible that ethanol inhibits other receptor-mediated signaling pathways in SMCs. Nevertheless, the finding that abrogation of FGF and FGFR signaling specifically impairs SMC differentiation and growth implies a strict dependence on FGF of SMC growth behavior. Thus, the linkage between ethanol-induced inhibition of SMC growth in this study and the inhibition by ethanol of SMC proliferation in vivo and in vitro is compelling.

The inhibitory action of ethanol on several growth factors has been localized to their respective RTKs. These interactions have been best characterized for the insulin receptor (IR) and IGF-IRs. These receptors exhibit close homology, particularly within their catalytic domains. Ethanol inhibits tyrosine autophosphorylation of IR and IGF-IR in several cell types and variably inhibits the tyrosine phosphorylation of key downstream signaling mediators, including IRS-1, IRS-2, and Shc and the activation of phosphatidylinositol 3-kinase. The locus of ethanol action on these receptors likely resides within the tyrosine kinase domain itself. Notably, ethanol inhibits the kinase activity of the minimal domain 35-kDa IR kinase domain. Similar inhibition of IGF-IR kinase activity has been observed (R. Rubin, unpublished data). Luo and Miller demonstrated that ethanol inhibits platelet-derived growth factor autophosphorylation. However, other RTKs appear to be insensitive to ethanol. Notably, the EGFR is not directly inhibited by ethanol in neuronal cells and hepatocytes. In the current study, mediators downstream of FGFR-2 displayed differential sensitivity to ethanol (see Figure 3). These differences likely reflect a myriad cellular contextual issues, including receptor expression, the localization and binding affinities of signaling mediators to RTKs, phosphorylation of nontyrosine residues, and tyrosine phosphatase activity.

In conclusion, we have demonstrated that the FGFR signaling pathway is a target for ethanol. Several growth factors promote SMC proliferation. Among them, angiotensin II, thrombin, endothelin-1, and HBEGF act as mitogens either directly or through activation of FGF expression. It will be of interest to assess whether the effect of ethanol on FGFR signaling is specific and how other mitogenic pathways that appear refractory to the alcohol-inhibitory activity, such as the EGFR, are affected by perturbation of the FGF autocrine growth mechanism. Our results are resonant with the impairment of SMC proliferation after inhibition of FGF signaling in vivo by FGF-specific antibodies and antisense DNA directed against the FGFR. These results serve as a basis for interpretation of the antimitogenic effect of ethanol on SMCs and support the idea that FGF2 plays a crucial role in initiating unrestrained SMC proliferation leading to atherosclerosis.

Acknowledgment
This work was supported by National Institutes of Health grants RO1 AA12680 and AA0976 (to R.R.)
Ghiselli et al

Ethanol Inhibition of Aortic SMC Proliferation

1813

References

Ethanol Inhibits Fibroblast Growth Factor–Induced Proliferation of Aortic Smooth Muscle Cells
Giancarlo Ghiselli, Jia Chen, Mohamad Kaou, Hazam Hallak and Raphael Rubin

Arterioscler Thromb Vasc Biol. 2003;23:1808-1813; originally published online August 7, 2003;
doi: 10.1161/01.ATV.0000090140.20291.CE
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/23/10/1808

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org/subscriptions/